(Q34207179)

31 July 2017

1 reference

title

Mechanisms of acute coronary syndromes and the potential role of statins (English)

1 reference

31 July 2017

main subject

acute coronary syndrome

1 reference

Dupuis J

1

1 reference

31 July 2017

language of work or name

1 reference

1 February 2001

1 reference

Atherosclerosis. Supplements

31 July 2017

published in

1 reference

31 July 2017

volume

2

1 reference

31 July 2017

issue

1

1 reference

31 July 2017

page(s)

9-14

1 reference

Lipid lowering and plaque regression. New insights into prevention of plaque disruption and clinical events in coronary disease

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2800%2900004-0

7 January 2021

Coronary Plaque Disruption

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2800%2900004-0

7 January 2021

A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association.

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2800%2900004-0

7 January 2021

Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2800%2900004-0

7 January 2021

Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2800%2900004-0

7 January 2021

Molecular bases of the acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2800%2900004-0

7 January 2021

Oxidized low-density lipoprotein regulates matrix metalloproteinase-9 and its tissue inhibitor in human monocyte-derived macrophages.

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2800%2900004-0

7 January 2021

Cytokines and growth factors positively and negatively regulate interstitial collagen gene expression in human vascular smooth muscle cells.

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2800%2900004-0

7 January 2021

Activation of monocyte/macrophage functions related to acute atheroma complication by ligation of CD40: induction of collagenase, stromelysin, and tissue factor.

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2800%2900004-0

7 January 2021

C-reactive protein colocalizes with complement in human hearts during acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2800%2900004-0

7 January 2021

Serum C-reactive protein concentration in acute myocardial infarction and its relationship to mortality during 24 months of follow-up in patients under thrombolytic treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2800%2900004-0

7 January 2021

Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2800%2900004-0

7 January 2021

Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2800%2900004-0

7 January 2021

Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2800%2900004-0

7 January 2021

Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators.

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2800%2900004-0

7 January 2021

Inhibition of proinflammatory cytokine production by pravastatin

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2800%2900004-0

7 January 2021

Requirement for mevalonate in acetylated LDL induction of cholesterol esterification in macrophages

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2800%2900004-0

7 January 2021

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2800%2900004-0

7 January 2021

Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): Reduction in atherosclerosis progression and clinical events

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2800%2900004-0

7 January 2021

Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2800%2900004-0

7 January 2021

Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2800%2900004-0

7 January 2021

Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2800%2900004-0

7 January 2021

Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2800%2900004-0

7 January 2021

Effects of pravastatin sodium and simvastatin on plasma fibrinogen level and blood rheology in type II hyperlipoproteinemia.

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2800%2900004-0

7 January 2021

Pravastatin therapy in hyperlipidemia: effects on thrombus formation and the systemic hemostatic profile

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2800%2900004-0

7 January 2021

Effect of atorvastatin on plasma fibrinogen

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2800%2900004-0

7 January 2021

Lovastatin therapy in hypercholesterolemia: effect on fibrinogen, hemorrheologic parameters, platelet activity, and red blood cell morphology

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2800%2900004-0

7 January 2021

Effects of long-term treatment with lovastatin on the clotting system and blood platelets

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2800%2900004-0

7 January 2021

Hemorheologic and coagulative pattern in hypercholesterolemic subjects treated with lipid-lowering drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2800%2900004-0

7 January 2021

Randomized placebo-controlled study of the effects of simvastatin on haemostatic variables, lipoproteins and free fatty acids. The Oxford Cholesterol Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2800%2900004-0

7 January 2021

Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Atorvastatin Study Group I.

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2800%2900004-0

7 January 2021

Effects of lovastatin therapy on plasminogen activator inhibitor-1 antigen levels

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2800%2900004-0

7 January 2021

Effect of Fluvastatin on Lipids and Fibrinolysis in Coronary Artery Disease

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2800%2900004-0

7 January 2021

Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2800%2900004-0

7 January 2021

Independent prognostic value of elevated C-reactive protein in unstable angina

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2800%2900004-0

7 January 2021

Inhibition of proliferation of human smooth muscle cells by various HMG-CoA reductase inhibitors; comparison with other human cell types

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2800%2900004-0

7 January 2021

10.1016/S1567-5688(00)00004-0

Identifiers

DOI

1 reference

31 July 2017

1 reference